Roche Holding AG (ETR:RHO)

Market Cap	326.49B +45.0%
Revenue (ttm)	68.05B +1.5%
Net Income	13.83B +55.6%
EPS	n/a
Shares Out	n/a
PE Ratio	23.60
Forward PE	18.38
Dividend	9.70 (2.51%)
Ex-Dividend Date	Mar 27, 2025

Volume	252
Average Volume	274
Open	385.20
Previous Close	384.60
Day's Range	384.40 - 390.00
52-Week Range	272.60 - 391.80
Beta	n/a
RSI	65.45
Earnings Date	Jan 29, 2026

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1896
• Employees: 103,249
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: RHO

Financial Performance

In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.

Financial numbers in CHF